We are live on ! Find out more
HQL

abrdn Life Sciences Investors

56 hedge funds and large institutions have $61M invested in abrdn Life Sciences Investors in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 14

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

2% more funds holding

Funds holding: 5556 (+1)

1% more capital invested

Capital invested by funds: $60.1M → $61M (+$895K)

0.59% more ownership

Funds ownership: 14.44%15.02% (+0.59%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
56
Holders Change
+1
Holders Change %
+1.82%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
6
Increased
23
Reduced
14
Closed
5
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q1 2018 in Review

56 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2018, worth a combined $61M — up 1.5% from $60.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new HQL positions and 5 closed out — a net gain of 1 holder — while 23 added to existing stakes and 14 trimmed.

The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $1.11M. The largest seller was LPL Financial, cutting an estimated $825K.

  • 56 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2018, up from 55 in Q4 2017.
  • Funds reported $61M of abrdn Life Sciences Investors stock for Q1 2018, up 1.5% quarter-over-quarter.
  • 6 funds opened new abrdn Life Sciences Investors positions in Q1 2018 and 5 closed out, a net change of +1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q1 2018 was Wolverine Asset Management, an estimated $1.11M added.
  • The largest abrdn Life Sciences Investors seller in Q1 2018 was LPL Financial, an estimated $825K sold.

Based on aggregated 13F filings for Q1 2018.